Symptomatic and asymptomatic biliary disorders during lenvatinib treatment for advanced thyroid cancer is an underestimated problem.

Symptomatic and asymptomatic biliary disorders during lenvatinib treatment for advanced thyroid cancer is an underestimated problem. Thyroid. 2020 Jul 29;: Authors: Agate L, Puleo L, Giani C, Valerio L, Molinaro E, Elisei R Abstract This letter is to confirm and support the data of Nervo et al, recently published on Thyroid journal, and showing a relevant prevalence of biliary disorders in patients affected by advanced thyroid cancer (TC) and treated with lenvima. We also observed a similar prevalence of gallbladder and/or biliary disease in a bigger series of TC treated with lenvima: by combining the Nervo et al. and our data the prevalence of this adverse event is of 16/118 (13.5%) and it seems independent from the starting daily dose. Only few differences have been observed: in our series some patients developed the adverse event even several months of treatment although the median time of onset was 3 months, some patients were asymptomatic and the disease was discovered at CT scan, some patients completely recover after the daily dose reduction and did not need to be operated. PMID: 32723011 [PubMed - as supplied by publisher]
Source: Thyroid : official journal of the American Thyroid Association - Category: Endocrinology Tags: Thyroid Source Type: research